title: Risk factors for acquisition of extended-spectrum β-lactamase-producing Escherichia coli in an urban county hospital.
abstract: BACKGROUND
  Better characterization of risk factors for extended-spectrum β-lactamase (ESBL)-producing bacteria is important for prevention, control, and treatment. This study aimed to identify risk factors for ESBL-producing Escherichia coli in a population of patients at an acute care urban teaching hospital.
  
  
  METHODS
  A matched case-control study was performed. Cases comprised adults with ESBL E coli isolated from any source and matched with controls on year of hospitalization. One control group included patients with non-ESBL E coli, and a second control group consisted of patients with another resistant bacterium with well-characterized risk factors, Pseudomonas aeruginosa.
  
  
  RESULTS
  There were 93 subjects in each group. Risk factors associated with ESBL cases compared with both control groups in a univariate model included sex, age, comorbidity, health care facility residence, recent hospitalization, and hemodialysis. In multivariate analysis, only Charlson comorbidity score remained significant between the cases and both control groups. Recent receipt of antibiotics was a risk factor for ESBL E coli versus non-ESBL E coli but not versus P aeruginosa.
  
  
  CONCLUSIONS
  Underlying comorbid illness appears to be a robust risk factor for acquisition of ESBL-producing E coli. Antibiotic use is a less clear risk factor and may be a surrogate for health care exposure in general.
authors.affiliation: Division of Infectious Diseases, Department of Internal Medicine, San Francisco General Hospital, University of California San Francisco, USA. sarah.doernberg@ucsf.edu
authors.forename: Sarah B
authors.initials: SB
authors.lastname: Doernberg
authors.forename: Lisa G
authors.initials: LG
authors.lastname: Winston
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002140:California / Q000453:epidemiology; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000382:microbiology; D016022:Case-Control Studies; D015897:Comorbidity; D004926:Escherichia coli / Q000187:drug effects / Q000302:isolation & purification*; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology / Q000635:transmission; D005260:Female; D006784:Hospitals, Teaching; D006786:Hospitals, Urban; D006801:Humans; D008107:Liver Diseases / Q000453:epidemiology / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000453:epidemiology / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification; D012307:Risk Factors; D001618:beta-Lactamases / Q000096:biosynthesis*
chemical_list: D000900:Anti-Bacterial Agents; D001618:beta-Lactamases